Results 71 to 80 of about 328,224 (217)

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis

Frontiers in Oncology
AimThis study comprehensively assesses the incidence and profiles of treatment-related adverse events (trAEs) of immune checkpoint inhibitor (ICI)-based therapies across cancer at various sites.MethodsWe systematically searched the PubMed, Embase, and ...
Xin Shen, Jun Yang, Geng Qian, Mingyu Sheng, Yu Wang, Guohui Li, Jiaqing Yan   +6 more
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Understanding the Burden of Orofacial Involvement and Patient Treatment Preferences in Systemic Sclerosis: Results From a Large International Survey

Arthritis Care &Research, EarlyView.
Objective Orofacial manifestations are significantly impactful in patients with systemic sclerosis (SSc) yet remain understudied, with no dedicated clinical guidelines to inform their management. Methods An international online survey comprised38 questions addressing orofacial manifestations of SSc, including patients’ confidence in their treating ...
Eleni Deligianni, Lee Shapiro, Deana Gibbs, Zsuzsanna H. McMahan, Michael Hughes   +4 more
wiley   +1 more source

Small‐Bowel Capsule Endoscopy in Immune‐Mediated Enterocolitis: A Case Series of Four Patients

JGH Open
Immune checkpoint inhibitors (ICIs) have emerged as a cornerstone of cancer immunotherapy but are associated with immune‐mediated adverse events (imAEs), including gastrointestinal toxicities.
Masayuki Orikasa, Tomoyoshi Shibuya, Hirotaka Ishino, Masashi Omori, Rina Odakura, Masao Koma, Kentaro Ito, Takafumi Maruyama, Kei Nomura, Dai Ishikawa, Mariko Hojo, Akihito Nagahara   +11 more
doaj   +1 more source

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, EarlyView.
Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta‐Analysis of Observational Studies and Randomized Controlled Trials

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Immune checkpoint inhibitors (ICIs) have uncommon associations with cardiotoxicity, yet these cardiotoxic effects are associated with high mortality.
Akash Sharma, Grace Alexander, Jian H. Chu, Artemis Markopoulos, Gilgamish Maloul, Muhammad Talha Ayub, Mary J. Fidler, Tochukwu M. Okwuosa   +7 more
doaj   +1 more source

Extending Service Beyond Active Duty: Generalizability of Rheumatoid Arthritis Research Conducted Among U.S. Veterans

Arthritis Care &Research, Accepted Article.
Biomedical research involving United States Veterans continues to advance healthcare beyond the Veterans Health Administration. This is particularly true in rheumatoid arthritis (RA), where Veteran‐centric research has uncovered novel insights into pathogenesis, risk factors, and disease manifestations, informing clinical care and research across both ...
Austin M. Wheeler, Joshua F. Baker, Jennifer L. Barton, Maria I. Danila, Tate M. Johnson, Kamini Kuchinad, Kaleb Michaud, Amir A. Razmjou, J. Steuart Richards, Namrata Singh, Isaac D. Smith, Katherine D. Wysham, Grant W. Cannon, Bryant R. England, Amy Joseph, Deana Lazaro, Katherine P. Liao, Courtney Loecker, Andreas Reimold, Beth I. Wallace, Ted R. Mikuls   +20 more
wiley   +1 more source

Immune-Related Dermatologic Reactions in Cancer Patients Undergoing Immunotherapy: A Case Series

Indian Journal of Medical and Paediatric Oncology
Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm across various malignancies by reactivating T cell responses against tumor cells.
Raja Chhabra, Chandragouda Dodagoudar, Sajjan Rajpurohit, Aditya Vidushi, Versha Kumari, Md Ali Osama   +5 more
doaj   +1 more source

Associations of Frailty With the Risk of Incident Cancer and Cancer‐Related Mortality in Veterans With Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Objective This study investigated the association between frailty and cancer incidence and mortality in patients with rheumatoid arthritis (RA). It aimed to identify how frailty influences cancer risk and cancer‐specific outcomes. Methods This retrospective cohort study analyzed data from the Veterans’ Affairs Rheumatoid Arthritis Registry (2002–2023).
Bhavik Bansal, Aaron Baraff, Katherine Wysham, James S. Andrews, Bryant R. England, Ted R. Mikuls, Joshua Baker, Kaleb Michaud, Alexa Meara, Una Makris, Carolyn Presley, Ariela Orkaby, Namrata Singh   +12 more
wiley   +1 more source

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Current Oncology
The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs).
Parneet K. Cheema, Marco A. J. Iafolla, Husam Abdel-Qadir, Andrew B. Bellini, Nazira Chatur, Natasha Chandok, Vikram R. Comondore, Morven Cunningham, Ilana Halperin, Anne B. Hu, Diana Jaskolka, Saeed Darvish-Kazem, Masud H. Khandaker, Abhijat Kitchlu, Jasdip S. Sachdeva, Shane Shapera, Nicholas R. J. Woolnough, Massey Nematollahi   +17 more
doaj   +1 more source